Commercialisation

  • Regulation of In Vivo CAR‑T Therapies

    Regulation of In Vivo CAR‑T Therapies

    Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…

  • Infectious Diseases and Vaccine Landscape 2026

    Infectious Diseases and Vaccine Landscape 2026

    Why Australia and New Zealand are strategically positioned for successful clinical trials. The global infectious disease environment continues to shift at pace in 2026, driven by: Influenza remains the clearest example of how quickly pathogens can adapt, and how the industry must respond. A newly dominant influenza A(H3N2) variant, commonly referred to as the “subclade…

  • Regulatory Strategy for Drug and Device Development

    Regulatory Strategy for Drug and Device Development

    Regulatory Strategy for Drug and Device Development. Why it must start on Day One. In the fast-paced world of life sciences innovation, the drive to “get moving” can be irresistible. Teams dive into development, eager to demonstrate progress.Yet the companies that succeed long-term are those that pause first to plan, align, and build a regulatory…

  • TGA Provisional Registration Pathway Australia

    TGA Provisional Registration Pathway Australia

    TGA Provisional Registration: Accelerating Patient Access to Medicines in Australia In Australia, the Therapeutic Goods Administration (TGA) offers a provisional registration pathway for prescription medicines. This pathway enables earlier patient access to certain promising new medicines, based on preliminary clinical data. In other markets, comparable processes may be known as conditional approval, or similar. Eligible…

  • Choosing the Right Regulatory Affairs Consultant

    Choosing the Right Regulatory Affairs Consultant

    Whether you are part of an established team, a start-up, an SME, or a founder, navigating the stringent requirements of the Medical Technology, Biotechnology, and Pharmaceutical (MTP) sectors can be complex and challenging. This is where partnering with the right Regulatory Affairs Consultant becomes invaluable. Understanding the Role of a Regulatory Affairs Consultant A regulatory…

  • Medical Device Registration in Australia

    Medical Device Registration in Australia

    Key considerations in navigating the regulatory process to register a medical device in Australia. Registering a medical device in Australia is a complex but crucial process that ensures the safety and performance of devices entering the healthcare market. Navigating the regulatory requirements of the Therapeutic Goods Administration (TGA) can be daunting, particularly for new manufacturers…

  • How to Register a Medicine in Australia

    How to Register a Medicine in Australia

    Six ways to register a medicine in Australia: Understanding the complexities of medicine registration. In the dynamic landscape of pharmaceuticals, securing registration for a new medicine requires a nuanced understanding of regulatory procedures and individual client needs. The process involves meticulous planning and strategic vision to ensure successful registration. However, beyond the intricacies of registration,…

  • Moderna mRNA COVID-19 Vaccine Approved in Australia

    Moderna mRNA COVID-19 Vaccine Approved in Australia

    09 August, 2021 – Moderna mRNA COVID-19 Vaccine Approved The Therapeutic Goods Administration (TGA) has provisionally approved the Moderna mRNA COVID-19 vaccine for use in Australia, in record time. Australia’s fourth approved vaccine, one million doses are due to be released in the second half of September, 2021. The Spikevax (elasomeran) vaccine is provisionally approved…

  • Custom-made Medical Devices in Australia: Now it’s Personal(ised)

    Custom-made Medical Devices in Australia: Now it’s Personal(ised)

    Recent changes in TGA Medical Device Regulations In December 2020, TGA released a new Personalised Medical Device Guideline along with a suite of new names and definitions that have shaken up the niche and specialised Custom-made Medical Devices sector. The new guidance reflects amendments to the Therapeutic Goods (Medical Devices) Regulations 2002, meaning that compliance

Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.